Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson's Disease: Efficacy, Safety, and Tolerability Data from the Second Cohort …
用户xH737f_pTw7c
1个月前
66
10
已关闭
DOI:
文献链接:
其他信息:
G Corcoran, A Karunakara, B Vaughn…
Movement …, 2021
ovid.com
… previously known as OXB-102, uses a … clinically relevant effect. Further evaluation of ALPD is planned using a higher dose/volume open label cohort followed by a sham-controlled study…

